Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Spero Therapeutics Inc (Spero Therapeutics) is a clinical-stage biopharmaceutical company. It focuses on developing new therapies for patients with rare diseases and multidrug-resistant bacterial infections. The company's pipeline product is Tebipenem HBr, an oral carbapenem intended for the treatment of complicated urinary tract infections and acute pyelonephritis. It targets drug-resistant bacteria, providing a potent at-home alternative to IV therapy to help patients avoid hospitalization. The company operates through its subsidiaries in Australia and the UK. Spero Therapeutics is headquartered in Cambridge, Massachusetts, the US.
Headquarters
United States of America
Address
14th Floor, 675 Massachusetts Avenue, Cambridge, 02139
Website
www.sperotherapeutics.com
Telephone
1 857 2421600
No of Employees
32
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
SPRO (NASD)
Revenue (2024)
$48.0M
-53.8%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-400.6%
(2024 vs 2023)
Market Cap*
$147.1M
Net Profit Margin (2024)
XYZ
-750.2%
(2024 vs 2023)
* As of and is in US$
Products and Services
| Products |
|---|
| Pipeline |
| Tebipenem HBr: Complicated Urinary Tract Infection (cUTI) and Acute Pyelonephritis (AP) |
Competitor Comparison
| Key Parameters | Spero Therapeutics Inc | Merck & Co Inc | Pfizer Inc | Shionogi & Co Ltd | Insmed Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | Japan | United States of America |
| City | Cambridge | Rahway | New York City | Osaka | Bridgewater |
| State/Province | Massachusetts | New Jersey | New York | Osaka | New Jersey |
| No. of Employees | 32 | 73,000 | 81,000 | 4,959 | 1,271 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Frank E. Thomas | Chairman | Executive Board | 2025 | 55 |
| Sath Shukla | Director | Executive Board | 2023 | 53 |
| Esther Rajavelu | Chief Financial Officer; Chief Executive Officer | Senior Management | 2025 | 46 |
| Timothy Keutzer | Chief Operating Officer | Senior Management | 2023 | 57 |
| Kamal Hamed, M.D. | Chief Medical Officer | Senior Management | 2022 | 64 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer